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OBJECTIVES: To construct and analyze a Structural Equation
Model (SEM) for Early Retirement (ER) of schizophrenia
patients in Germany and potential factors predisposing to ER.
METHODS: Based on a set of data consisting of 20 variables
collected retrospectively for 305 early retired and 317 not early
retired German Schizophrenia outpatients (mean age 38.7 years,
mean age at ﬁrst diagnosis 30.5 years), a SEM (Muthen &
Muthen) was constructed using MPlus 3.31 to model the rela-
tionship of potential predisposing factors among each other and
with the dichotomous outcome ER. RESULTS: The ﬁnal model
was based on 497 observations and included ER and the vari-
ables Disease Severity (CGI scale), Course of Disease (categories
from “continuous” to “remission”), Caring Situation (housing
and care information), Age, and Treatment with Atypical
Antipsychotics. Age (0.117), Caring Situation (0.134), Course of
Disease (−0.196) and Disease Severity (0.574) were directly
related to the outcome Early Retirement (values between 0 and
+/−1, positive: factor predisposes to ER). Indirect effects were
shown for Treatment with Atypical Antipsychotics, which nega-
tively inﬂuenced Disease Severity (−0.110); Age, which nega-
tively inﬂuenced the probability to receive Treatment with
Atypical Antipsychotics (−0.155); Caring Situation, which posi-
tively inﬂuenced Disease Severity (0.189); and Course of Disease,
which negatively inﬂuenced Disease Severity (−0.410). With a
variability of 0.538 explained and with all relationships signiﬁ-
cant, the model was highly valid. CONCLUSIONS: Disease
Severity is the central factor inﬂuencing the propensity of
German Schizophrenia Patients to ER. Course of Disease and
Caring Situation impact ER directly and also indirectly via
Disease Severity. Treatment with Atypical Antipsychotics reduces
the propensity to ER indirectly through the factor Disease Sever-
ity. Especially for ER as a dichotomous variable, SEMs can be
successfully used to analyze complex relationships between a set
of factors and the outcome of interest. Indirect effects can be
directly analyzed and displayed.
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OBJECTIVES: An interim analysis of changes in illness severity
(Clinical Global Impression-Severity, CGI-S) and functioning
(Global Assessment of Functioning, GAF) in Belgian patients
with schizophrenia switched to RLAI as part of their routine
management and followed up for 6 months. METHODS: e-
STAR is an observational study of patients using a web-based
data collection tool. Data are collected for 12 months retro-
spectively and 2 years prospectively for patients commencing a
new antipsychotic treatment. Data reported here are for those
patients who continue RLAI for 6 months. RESULTS: In Belgium
400 patients have been enrolled. Of the 206 patients with 6
months follow-up data, 86% (178 patients) have continued
treatment with RLAI. Mean (SD) age of this group of patients
was 40.3 (13.7) years. Mean (SD) duration of illness was 10.4
(10.3) and 62.4% were male. Most frequent reasons for a switch
to RLAI were poor compliance (38.2% of patients) and need for
maintenance therapy (23.5%). Mean (SD, median) CGI score 
at baseline was 4.5 (1.0, 5.0) (n = 142) with 16.9% patients
having very mild/mild illness, 30.3% moderate, and 52.8%
marked/severe/very severe. At 6 months, mean (SD, median) CGI
score was signiﬁcantly lower at 3.5 (1.1, 3.0) (p < 0.001) with
52.1% having mild/very mild illness (p < 0.001 versus baseline),
29.6% moderate and 18.3% marked/severe/very severe (p <
0.001). Similarly mean (SD, median) GAF score improved from
45.3 (13.6, 45.0) at baseline to 59.6 (13.7, 60.5) at 6 months (n
= 142) (p < 0.001). RLAI was well tolerated; 88.8% of patients
reported no adverse events (AEs). Serious AEs were reported in
8 (4.5%) patients, none of which were unequivocally related to
RLAI. CONCLUSIONS: These interim data show that patients
who switched to RLAI exhibit signiﬁcant improvements from
baseline in clinical and functional outcomes after 6 months of
continual treatment. Further follow-up is ongoing.
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OBJECTIVES: To examine whether there is a reduced incidence
of suicidal ideation, violent behaviour, and deliberate self-harm
in patients with schizophrenia after six months of treatment with
long-acting risperidone injection (RLAI). METHODS: e-STAR 
is an ongoing, multinational, non-interventional, observational
registry that records outcomes following a change in antipsy-
chotic drug treatment during the management of patients with
schizophrenia in a normal clinical practice setting. The incidence
of suicidal ideation, violent behaviour, and deliberate self-harm
(secondary objectives of the registry) were assessed at baseline
and after six months of treatment with RLAI. RESULTS: Interim
data are available for a total 1571 patients in Spain (n = 1005),
Belgium (n = 178), and Australia (n = 388). There was a statis-
tically signiﬁcant reduction in the incidence of suicidal ideation
in Spanish patients (9.4% at baseline versus 0.4% at six months,
p < 0.001) and Belgian patients (6.2% versus 0.6%, p = 0.004)
after six months of treatment with RLAI. Although there was a
reduction in suicidal ideation in Australian patients (6.4% versus
5.2%), this was not statistically signiﬁcant. There was a statisti-
cally signiﬁcant reduction in violent behaviour in Spanish
patients (11.1% versus 0.3%, p < 0.001), Belgian patients
(11.2% versus 0.6%, p < 0.001), and Australian patients (9.0%
versus 4.9%, p < 0.02) after six months. In Spain, there was a
decreased incidence of deliberate self-harm after six months of
treatment (3% versus 0%) and this was also seen in Belgian
patients (1.7% to 0%). In Australia, the incidence of deliberate
self-harm was unchanged at 2.8%. CONCLUSIONS: There was
a reduction in suicidal ideation and violent behaviour after six
months of treatment with RLAI in Spanish, Belgian, and Aus-
tralian patients with schizophrenia.
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OBJECTIVES: This is a 6-month interim analysis of patients in
Spain who are enrolled in e-STAR, and initiated on RLAI during
